)
Biocon Ltd, India's largest publicly held biotech company, and CytoSorbents Corporation, based in the United States, have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb, a therapy for the management of sepsis.
Biocon and CytoSorbents will initially focus on the treatment of sepsis - the end result of an excessive immune response to infection. The effective treatment of sepsis needs to address two components – the infection and the over-activation of the immune system.
By combining Biocon’s critical care antibiotics to treat the infection that are also compatible with CytoSorb therapy to modulate the immune response, the two companies will provide solution for sepsis management in the market.
More From This Section
CytoSorb is designed to target the prevention or treatment of organ failure which is the cause of nearly half of all deaths in the intensive care unit. If left unchecked, ‘cytokine storm’ caused by excessive cytokine production can cause massive inflammation, organ failure and death in common life-threatening conditions such as sepsis, burn injury, trauma, lung injury, and pancreatitis.
CytoSorb is clinically proven to control cytokine storm in critically-ill patients by reducing key cytokines in blood by 30-50%. It also works easily with standard dialysis machines used in hospitals.
Kiran Mazumdar Shaw, Chairperson & Managing Director, Biocon Ltd, said, “We believe our partnership with CytoSorbents will enable us to address the huge unmet need of sepsis management in India and emerging markets. CytoSorb can provide an effective solution to physicians to treat critically ill patients suffering from sepsis."
Dr. Phillip Chan, Chief Executive Officer and President, CytoSorbents, said, “We are very pleased to enter into this initial agreement with Biocon to bring our potentially life-saving therapy to the people of India and other emerging markets. Unlike any other previous approach, CytoSorbattacks sepsis from multiple angles – reducing cytokine storm, reducing many deadly bacterial toxins, and directing immune cells to target the infection while avoiding damage to otherwise healthy organs. When combined with Biocon’s critical care antibiotics, it is an ideal broad spectrum strategy to fight sepsis."
